GGrantIndex
← Search

Leadership, Planning and Evaluation

$678,947P30FY2018CANIH

Northwestern University At Chicago, Evanston IL

Investigators

Linked publications, trials & patents

Trial NCT07639528Trial NCT07594626Trial NCT07594548Trial NCT07290543Trial NCT07261657Trial NCT07178301Trial NCT07169617Trial NCT07050186Trial NCT07042919Trial NCT06959641Trial NCT06813898Trial NCT06723457Trial NCT06630416Trial NCT06571734Trial NCT06499870Trial NCT06410248Trial NCT06327477Trial NCT06247540Trial NCT06244004Trial NCT06242834Trial NCT06184750Trial NCT06164275Trial NCT06137651Trial NCT06062498Trial NCT06060587Trial NCT06022822Trial NCT05879250Trial NCT05852041Trial NCT05802186Trial NCT05744739Trial NCT05733000Trial NCT05620771Trial NCT05576896Trial NCT05545150Trial NCT05453799Trial NCT05419011Trial NCT05411107Trial NCT05236036Trial NCT05202782Trial NCT05093387Trial NCT04931017Trial NCT04910425Trial NCT04795869Trial NCT04767984Trial NCT04753216Trial NCT04576104Trial NCT04550481Trial NCT04250051Trial NCT04227028Trial NCT04200443Trial NCT04049227Trial NCT04047706Trial NCT04033432Trial NCT04009044Trial NCT03854474Trial NCT03812562Trial NCT03742258Trial NCT03723915Trial NCT03704714Trial NCT03513484Trial NCT03317405Trial NCT03278925Trial NCT03226249Trial NCT03213041Trial NCT03146650Trial NCT03077828Trial NCT03070002Trial NCT03061188Trial NCT03048500Trial NCT03044730Trial NCT03036930Trial NCT03020017Trial NCT02993159Trial NCT02968810Trial NCT02965703Trial NCT02901899Trial NCT02892734Trial NCT02871323Trial NCT02861040Trial NCT02847559Trial NCT02837029Trial NCT02819804Trial NCT02808143Trial NCT02805868Trial NCT02794883Trial NCT02774681Trial NCT02743364Trial NCT02720484Trial NCT02694809Trial NCT02536794Trial NCT02530619Trial NCT02530502Trial NCT02530125Trial NCT02481310Trial NCT02365480Trial NCT02357810Trial NCT02314156Trial NCT02242097Trial NCT02237183Trial NCT02232516

Abstract

ABSTRACT ? PLANNING AND EVALUATION The Lurie Cancer Center (LCC) has a well-developed system for planning and evaluation. As new LCC Director, Dr. Platanias established a new Senior Leadership team, with well-defined roles and responsibilities: (1) Maha Hussain, M.D. was appointed as Deputy Director, (2) Kathleen Green, Ph.D. as Associate Director for Basic Sciences Research, (3) Massimo Cristofanilli, M.D., as Associate Director for Translational Research, (4) Milan Mrksich, Ph.D. as Associate Director for Shared Resources, (5) Aleksandar Zafirovski, M.B.A., as Associate Director for Administration and (6) Jeffrey Wayne, M.D. as Associate Director for Clinical Operations. Among the Associate Directors continuing in their positions are (1) David Cella, Ph.D., for Cancer Prevention and Control Research, (2) John Crispino, Ph.D., for Education and Training and (3) Alexis Thompson, M.D., for Equity and Minority Health. This team works collectively as the Executive Committee (EC), which meets every two weeks and is the primary decision making body that sets the overall strategic direction of the Center. The EC provides direction in matters relevant to LCC operations, management, and policy and oversees all research activities. It also sets budgetary and fiscal priorities and reviews LCC membership. CCSG support is requested for all Senior Leadership positions except the position of Associate Director for Clinical Operations. In addition to the EC, there are several other governance structures that provide the primary means by which the LCC conducts planning and evaluation on an ongoing basis. These are the Scientific Research Council (SCRC), the Clinical Cancer Center Executive Council (CCCEC), the Program Leaders Committee (PLC) and the Internal and External Advisory Boards. The SCRC includes the Associate Directors and all Program and Shared Resource leaders/directors, and meets quarterly to review initiatives and provide input for research programs, shared resources and training/education. The PLC, a new committee established by Dr. Platanias, meets monthly to discuss joint initiatives within and between programs and provides important input to the EC. The External Advisory Board (EAB) is comprised of recognized leaders in clinical, basic and population sciences, biostatistics and center administration, and meets at least annually to review all aspects of LCC operations and initiatives. After his appointment as Director, Dr. Platanias increased the number of EAB members and made several new EAB appointments with input from other senior leaders. Additional planning input is provided by retreats, other Center advisory committees, surveys and ad hoc reviews. With careful planning and critical input from the different advisory groups, the Director initiated a new five-year strategic planning process, reorganized center research program membership, and created working groups to continue improving oversight and governance. These coordinated teams provide critical advice and guidance, ensuring that the LCC most effectively sets priorities and pursues objectives that promote its mission. CCSG support is requested for the activities of the EAB, which plays an essential role in the evaluation of the LCC?s programs and organization.

View original record on NIH RePORTER →